The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

NEXT Oncology enrolls first patient in Madrid phase I clinical research center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

NEXT Oncology – Madrid enrolled its first patient in March 2022 in an early phase clinical trial focused on metastatic triple negative breast cancer with an anti-drug conjugate used in monotherapy or in combination with antiPDL1. NEXT Oncology expanded to Spain in late 2021.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type. 
In Brief

VCU Massey, MD Anderson researchers awarded $7.3M grant to launch breast cancer clinical trial

Venkata Lokesh BattulaClinton YamA multidisciplinary team of researchers at VCU Massey Comprehensive Cancer Center and MD Anderson Cancer Center has been awarded a $7.3 million grant from the U.S. Department of Defense to fund a novel clinical trial targeting one of the most aggressive and hard-to-treat forms of breast cancer: metastatic triple-negative breast cancer. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account